Literature DB >> 17707756

Management of atrial fibrillation.

Gregory Y H Lip1, Hung-Fat Tse.   

Abstract

Atrial fibrillation is the most common sustained cardiac rhythm disorder, and confers a substantial mortality and morbidity from stroke, thromboembolism, heart failure, and impaired quality of life. With the increasingly elderly population in the developed world, as well as improvements in the management of myocardial infarction and heart failure, the prevalence of atrial fibrillation is increasing, resulting in a major public-health problem. This Review aims to provide an overview on the modern management of atrial fibrillation, with particular emphasis on pharmacological and non-pharmacological approaches. Irrespective of a rate-control or rhythm-control strategy, stroke prevention with appropriate thromboprophylaxis still remains central to the management of this common arrhythmia. Electrophysiological approaches could hold some promise for a curative approach in atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707756     DOI: 10.1016/S0140-6736(07)61300-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

1.  Vaccination and risk of lone atrial fibrillation in the active component United States military.

Authors:  Michael M McNeil; Susan K Duderstadt; Jennifer F Sabatier; Gina G Ma; Jonathan Duffy
Journal:  Hum Vaccin Immunother       Date:  2019-01-08       Impact factor: 3.452

2.  Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.

Authors:  Joachim R Ehrlich; Magdalena Kaluzny; Stefan Baumann; Ralf Lehmann; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2011-07-03       Impact factor: 5.460

3.  Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Walid Amara; Sotiris Antoniou
Journal:  Eur Heart J Suppl       Date:  2016-04-21       Impact factor: 1.803

Review 4.  Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease.

Authors:  Christiane Engelbertz; Holger Reinecke
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 5.  Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?

Authors:  James A Reiffel
Journal:  J Atr Fibrillation       Date:  2008-05-16

6.  The CHADS2 and CHA 2DS 2-VASc scores predict new occurrence of atrial fibrillation and ischemic stroke.

Authors:  Ming-Liang Zuo; Shasha Liu; Koon-Ho Chan; Kui-Kai Lau; Boon-Hor Chong; Kwok-Fai Lam; Yap-Hang Chan; Yuk-Fai Lau; Gregory Y H Lip; Chu-Pak Lau; Hung-Fat Tse; Chung-Wah Siu
Journal:  J Interv Card Electrophysiol       Date:  2013-02-07       Impact factor: 1.900

7.  Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.

Authors:  Pablo Alonso-Coello; Victor M Montori; M Gloria Díaz; Philip J Devereaux; Gemma Mas; Ana I Diez; Ivan Solà; Mercè Roura; Juan C Souto; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ignasi Gich; Holger J Schünemann; Gordon Guyatt
Journal:  Health Expect       Date:  2014-05-12       Impact factor: 3.377

8.  The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.

Authors:  Ahmad Husari; Atallah Beydoun; Amein Sheik Ammar; Joseph E Maakaron; Ali Taher
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

Review 9.  Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation.

Authors:  Andrea Tampieri; Anna Maria Rusconi; Tiziano Lenzi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

10.  Effect of Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers on patients following ablation of atrial fibrillation.

Authors:  Jeong-Hwan Park; Yong-Seog Oh; Ji-Hoon Kim; Woo-Baek Chung; Su-Sung Oh; Dong-Hyun Lee; Yun-Seok Choi; Woo-Seung Shin; Chul-Soo Park; Ho-Joong Youn; Wook-Sung Chung; Man-Young Lee; Ki-Bae Seung; Tae-Ho Rho; Jae-Hyung Kim; Soon-Jo Hong
Journal:  Korean Circ J       Date:  2009-05-28       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.